Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
 |
Int J Clin Pract Suppl. 1999 Jun;103:49-52. Unique Identifier : AIDSLINE MED/20087926
Gazzard B
Abstract: An interactive voting session at the end of the European symposium on evolving therapies provided an opportunity for panel discussion on various therapeutic options based on a series of case studies. The interactive voting and subsequent discussion focused on the preferred options for first-line, second-line and salvage therapy. In addition, issues of compliance and drug resistance were addressed. All case studies were entirely hypothetical and were projected into the future when it is anticipated that today's investigational drugs are likely to be available for general use.
000430
A0040880
Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .